Virgin Galactic Holdings, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Virgin Galactic Holdings, Inc. trades at $3.29 (market cap $498.02M), while State Street SPDR S&P Biotech ETF trades at $158.16. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| SPCE | XBI | |
|---|---|---|
Market Cap | $498.02M | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $7.52 | $164.28 |
52-Week Low | $2.17 | $86.92 |
Enterprise Value | $597.87M | — |
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.23, up 4.19% on the day, with a bullish technical signal from moving averages but overbought RSI levels near 91.63. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations of $240.14 million. Recent news highlights focus on upcoming Q2 2026 earnings and sector volatility amid SpaceX's market debut.
The outlook remains high-risk due to persistent unprofitability and cash burn, though recent quarterly EPS beats offer some optimism. Investment opportunity hinges on successful commercialization of space tourism, while risks include intense competition, funding needs, and execution challenges. Analyst sentiment is mixed with 29.41% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →